“(A) In general.—For purposes of paragraph (1)(B), the amount specified in this paragraph for a part B rebatable drug assigned to a billing and payment code for a calendar quarter is, subject to paragraph (4), the amount equal to the product of—
“(i) subject to subparagraph (B), the total number of billing units, as described in section 1847A(b)(6)(B), for such part B rebatable drug furnished under this part during the calendar quarter; and
“(ii) the amount (if any) by which—
“(I) the payment amount under subparagraph (B) or (C) of section 1847A(b)(1), as applicable, for such part B rebatable drug during the calendar quarter; exceeds
“(II) the inflation-adjusted payment amount determined under sub-paragraph (C) for such part B rebatable drug during the calendar quarter.
“(B) Excluded units.—For purposes of subparagraph (A)(i), the total number of billing
·HR 4663 TH
